Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910657 · ClinicalTrials.gov registry record · Phase 1
IDOV-Immune for Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by ViroMissile.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 6
- Study locations
NCT06910657 is a Phase 1 study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by ViroMissile. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT06910657, a Phase 1 study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by ViroMissile.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Conditions Studied
Interventions
- BIOLOGICAL IDOV-Immune (oncolytic vaccinia virus)
Study Locations (6)
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
New South Wales
- Royal North Shore Hospital - Saint Leonards
- Westmead Hospital - Westmead
Missouri
- Washington University School of Medicine - St Louis
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06910657
The ClinicalTrials.gov registry entry for NCT06910657 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is ViroMissile, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IDOV-Immune (oncolytic vaccinia virus) is the first listed.
NCT06910657 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, New South Wales, Missouri.
Frequently Asked Questions
What is clinical trial NCT06910657 about?
NCT06910657 is a clinical study titled "IDOV-Immune for Advanced Solid Tumors". This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potenti...
What is the current status of trial NCT06910657?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2025-08-25. Estimated completion is 2027-05-31.
What conditions does trial NCT06910657 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma.
What interventions are being tested in trial NCT06910657?
The interventions under investigation include: IDOV-Immune (oncolytic vaccinia virus) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06910657?
This trial is sponsored by ViroMissile, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910657 being conducted?
This trial has 6 study locations across Missouri, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.